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CristaeDysregulation of mitochondrial structure and function has emerged as a central factor in the pathogenesis of
Parkinson's disease and related parkinsonian disorders (PD). Toxic and environmental injuries and risk
factors perturb mitochondrial complex I function, and gene products linked to familial PD often affect
mitochondrial biology. Autosomal recessive mutations in PTEN-induced kinase 1 (PINK1) cause an L-DOPA
responsive parkinsonian syndrome, stimulating extensive interest in the normal neuroprotective and
mitoprotective functions of PINK1. Recent data from mammalian and invertebrate model systems converge
upon interactions between PINK1 and parkin, as well as DJ-1, α-synuclein and leucine rich repeat kinase 2
(LRRK2). While all studies to date support a neuroprotective role for wild type, but not mutant PINK1, there is
less agreement on subcellular compartmentalization of PINK1 kinase function and whether PINK1 promotes
mitochondrial ﬁssion or fusion. These controversies are reviewed in the context of the dynamic
mitochondrial lifecycle, in which mitochondrial structure and function are continuously modulated not
only by the ﬁssion–fusion machinery, but also by regulation of biogenesis, axonal/dendritic transport and
autophagy. A working model is proposed, in which PINK1 loss-of-function results in mitochondrial reactive
oxygen species (ROS), cristae/respiratory dysfunction and destabilization of calcium homeostasis, which
trigger compensatory ﬁssion, autophagy and biosynthetic repair pathways that dramatically alter
mitochondrial structure. Concurrent strategies to identify pathways that mediate normal PINK1 function
and to identify factors that facilitate appropriate compensatory responses to its loss are both needed to halt
the aging-related penetrance and incidence of familial and sporadic PD.
© 2009 Elsevier B.V. All rights reserved.1. Mitochondrial pathobiology is centrally implicated in
Parkinson's disease
Parkinson's disease (PD) is a debilitating movement disorder that
affects about amillion people in North America, andwhich is expected
to increase as the population grows older. Studies employing
Mendelian models of parkinsonian neurodegeneration implicate an
exciting convergence with mechanisms identiﬁed from studies of
Parkinson's disease patient tissues and intoxication related to drug or
environmental exposures [1,2]. In short, these three major approaches
to studying PD converge upon perturbations in mitochondrial
structure, function and distribution [3]. There are currently no
therapies to slow disease progression, although presumed loss-of-
function mutations in autosomal recessive families result in acceler-
ated disease presenting at younger ages. Thus, studying the regulation
and function of the wild type gene products may yield important
therapeutic insights to prevent or delay onset and progression of PD in
general [4–7].
The proteins involved in autosomal recessive PD include parkin,
PTEN-induced kinase 1 (PINK1), DJ-1 and ATP13A2 [8–11]. Parkin is anll rights reserved.E3 ubiquitin ligase, and impaired proteasome function has been
described in sporadic PD [5,12]. Mitochondria are central to the
actions of parkinsonian toxins such as 1-methyl-4-phenyl-1,2,3,6-
tetrahydroxypyridine (MPTP) [13], rotenone [7] and 6-hydroxydopa-
mine (6-OHDA) [14,15], and PINK1 represents the only kinase known
to exhibit a canonical N-terminal mitochondrial localization signal
[10]. ATP13A2 is a lysosomal ATPase, and dysregulation of macro-
autophagy [16–18] and chaperone-mediated autophagy [19,20] has
been shown in multiple models of dopaminergic neuronal injury.
Finally, oxidative stress has long been considered a central factor in PD
mechanisms based upon human tissue studies and PD toxin models
[21,22]. Data showing that DJ-1 localizes to mitochondria during
oxidative stress [6], where it exhibits peroxiredoxin-like activity [23],
lend further support to the concept of common pathways of
dopaminergic (DA) neurodegeneration that are potentially amenable
to therapeutic intervention [123].
2. Mitochondrial dynamics and neuronal differentiation
and function
Due to their polarized nature, proper distribution of mitochondria
within cellular subcompartments is particularly important in neurons.
Mitochondrial content in neuronal processes (axons, synapses and
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regulating outgrowth and synaptic remodeling into adulthood [24,25].
Disruption of neurite remodeling and plasticity due to old age and
disease likely contributes to memory loss and neurodegeneration.
Interestingly, the dynamic remodeling of pre-existing mitochondria
may play a more prominent role than biogenesis in regulating
mitochondrial content in neurites [26,27].
The classic view of mitochondrial dynamics focuses upon regula-
tion of mitochondrial ﬁssion and fusion, although several other
processes also regulate the steady state morphology and distribution
of mitochondria within neurons (Fig. 1). Mitochondrial fusion is
mediated by the inner membrane protein optic atrophy 1 (Opa1) and
two outer membrane mitofusins. In general, enhanced mitochondrial
fusion and connectivity play critical roles in conferring resistance to
many forms of cellular injury [28,29], potentially through enhanced
respiration, enhanced calcium buffering capacity or stabilization of
the mitochondrial genome [30]. Mutations in the fusion machinery
cause several forms of hereditary neurodegeneration, attesting to the
importance of proper ﬁssion–fusion dynamics in neurons [31].
Mitochondrial ﬁssion is mediated by cytosolic and outer mito-
chondrial membrane proteins including dynamin-related protein
(Drp1) and hFis1, which mediate mechanical constriction powered
by GTP hydrolysis. While Drp1-dependent mitochondrial ﬁssion can
limit injury associated with calcium waves [32], ﬁssion is often
associated with cell death. Fission is elicited by the PD neurotoxins 6-
OHDA [33] and rotenone [34], playing an important role in the
execution of apoptosis when occurring in conjunction with Bax
recruitment [35,36]. On the other hand, a basal level of mitochondrial
ﬁssion is important for cell division and mitochondrial trafﬁcking, and
dominant negative Drp1 homologues reduce both mitochondrial
content and functional plasticity of synapses [25,26]. Little is known
about the post-translational regulation of mitochondrial dynamics,Fig. 1. The lifecycle of a mitochondrion. There are multiple factors that regulate the
steady state distribution and morphology of the mitochondrial network in a cell.
Dynamic processes that regulate the normal mitochondrial lifecycle are linked by blue
arrows. Mitochondrial biogenesis is regulated by both nuclear and mitochondrial
transcription factors, targeted translational and protein trafﬁcking mechanisms and, in
neurons, activity-dependent transport of the entire organelle to meet functional
demands. A balance of ﬁssion and fusion events occurs continuously, and is tied into
axonal trafﬁcking in neurons and cell cycle in non-neuronal cells. A portion of
mitochondria isolated by ﬁssion undergoes basal autophagic turnover, releasing new
building blocks and unknown signals related to biogenesis (green dashed arrow). Most
injury states that have been studied promote mitochondrial ﬁssion (red arrow). While
ﬁssion involving bax-recruitment is necessary for cell death in some systems [35], the
role of ﬁssion in other injury contexts is less clear. We propose that ﬁssion serves
predominantly as an injury response to isolate damaged segments of the mitochondrial
network. Segments that can be repaired may refuse with other undamaged portions
(green arrow). Fission protects the remainder of the network against harmful calcium
ﬂuxes [32], and enhances retrograde transport and mitochondrial autophagy, which
serves to further sequester damaged mitochondria and reduce leakage of pro-death
mediators. If neither repair nor autophagy is sufﬁcient, or if degraded mitochondria are
ineffectively replaced [39], the balance tips to favor cell death (red dashed arrow).although sumoylation and phosphorylation of Drp1 have been
recently reported [28,37].
In addition to dynamic changes in mitochondrial ﬁssion/fusion
and trafﬁcking, there is growing evidence that autophagic degradation
plays a major role in regulating neurite morphology and mitochon-
drial content. Macroautophagy involves the regulated, membranous
engulfment of cytoplasmic cargo destined for lysosomal degradation
[38,39], and represents the only major degradative pathway for
organelles and insoluble proteins [40]. The autophagy machinery
includes conjugating enzymes required for attachment of ubiquitin-
fold proteins Atg12 and Atg8/microtubule-associated light chain
protein 3 (LC3) to nascent autophagic membranes [38]. RNAi knock-
down of Atg conjugation components is effective at inhibiting
induction of autophagy and mitophagy [16,18].
Mitochondrial autophagy (mitophagy) comprises an adaptive
response to hypoxia, mitochondrial damage or limiting amounts of
aerobic substrates in many cell types [41]. However, in cardiac muscle
and neuronal cells, which are dependent upon aerobic respiration,
robust mitophagy may also prove harmful [18,42,43]. Autophagy
induced by cerebral hypoxia exacerbates neuronal apoptosis in vivo
[44,45]. Since substantia nigra DA neurons exhibit decreased basal
mitochondrial content compared to other midbrain neurons, it has
been proposed that diminished reserves may render them more
susceptible to compromise of mitochondrial homeostasis during PD
pathogenesis [46]. We have postulated that the outcome of mitophagy
induction may depend upon the ability of neurons to replace
sequestered/degraded mitochondrial components with newly
synthesized replacements [39], given data suggesting deﬁcits in
nuclear import and transcription in 6-OHDA treated neuronal cells
and post-mortem PD tissues [47,48]. Interestingly, impaired mtDNA
replication has been implicated in PINK1 deﬁcient cells [49], although
evidence of compensatory mitochondrial and antioxidant transcrip-
tion have also been reported [50,51].
3. PINK1 is a novel neuroprotective kinase
PINK1 is a 581 amino acid protein with an N-terminal mitochon-
drial targeting signal, a putative transmembrane segment, a Ser/Thr
kinase domain, and a C-terminal regulatory domain (reviewed in
[52]). PINK1 was originally identiﬁed as a PTEN regulated message in
cancer cells, but showed no effects on cell proliferation [53]. A
homozygous G309Dmutation and a truncatingW437Xmutationwere
ﬁrst identiﬁed in consanguineous European PD families [10]. Subse-
quently, additional autosomal recessive PINK1 mutations, including
heterozygote compound mutations at E240K and L489P, were
identiﬁed in other PD families [54–57]. The possibility of PINK1
haploinsufﬁciency as a risk factor in sporadic PD has also been raised
[58–60]. Although meta-analysis reveals a nonsigniﬁcant odds ratio
for PINK1 heterozygotes, these patients may show accelerated disease
progression [61].
Mutations in familial PINK1 involve several regions of the protein
and speciﬁc effects are likely to vary depending upon the mutation
(reviewed in [52]). PD-associatedmutations in PINK1 can affect PINK1
stability and expression levels [62], its association with heat shock
protein 90 chaperones [63,64], or its ability to phosphorylate pan-
kinase substrates such as histone H1 and casein [65,66], although
neither mitochondrial import [62] nor ability to dimerize [67] appears
to be affected by the point mutations. C-terminal truncations of PINK1
are likely to affect function, as in vitro kinase activity of PINK1 is
regulated in different directions by portions of the C-terminal domain
[65,66].
Overexpression of wild type PINK1 confers protection from
proteasome inhibitor-mediated cell death [10], a property abolished
by PD-associated mutations [68], and PINK1 is found in mitochondria
involved in aggresomes [69]. Wild type, but not mutant, PINK1
protects from staurosporine-induced apoptosis [70], although this is
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vivo and MPP+ toxicity in vitro [71], and siRNA knockdown of PINK1
expression enhances susceptibility to MPP+ and rotenone [72].
Despite these striking effects on survival, few target pathways for
PINK1 have been identiﬁed. PINK1 phosphorylates the mitochondrial
heat shock protein 75 (also known as TNF receptor-associated protein
1) [73] and interacts with p38 MAPK in phosphorylating the
mitochondrial protease HtrA2 [74].
In addition to neuroprotection against pharmacologic injuries,
PINK1 can reduce injury associated with dominant genetic PDmodels.
Sporadic PD and autosomal dominant Parkinsonism is typically
characterized by Lewy bodies containing aggregated α-synuclein. In
recent years, α-synuclein has also been implicated in mitochondrial
degeneration, both in vitro [75] and in vivo [76]. PINK1 protects
against α-synuclein-mediated retinal degeneration in Drosophila [77].
In cultured cells, a truncated mutant PINK1 exacerbates A53T α-
synuclein toxicity [78] and PINK1 siRNA elicits proteasomal impair-
ment andα-synuclein aggregation [67]. The dominant G2019S leucine
rich repeat kinase 2 causes neurite degeneration through an
autophagic mechanism [17]. PINK1 overexpression protects against
G2019S LRRK2-mediated neurite injury (SJ Cherra and CT Chu,
unpublished data), while nematode lrk-1 is necessary for the
expression of pink-1 null phenotypes [79]. Given the broad neuropro-
tective properties of PINK1 in both toxic and genetic models of
parkinsonian injury, elucidating the normal function(s) of PINK1
holds much promise towards development of future therapies that
will be effective in multiple forms of PD.
4. PINK1 is a unique kinase directly targeted to mitochondria
(sometimes)
Following identiﬁcation of PINK1 as a PD-associated gene, it was
found to be broadly expressed in the cortex, striatum and brainstem
[80], with regulation by post-transcriptional mechanisms [81]. PINK1
represents the ﬁrst kinase to exhibit a canonical mitochondrial
targeting sequence. This consists of an N-terminal amphipathic helix
that is recognized by the translocase of the outer mitochondrial
membrane (TOM) [82]. PINK1 colocalizes with mitochondria in cells
[65] and in human brain tissues [83], but is also present in cytosolic
fractions [62,63]. In Drosophila, the rhomboid-7 mitochondrial
proteinase may be involved in processing both PINK1 and HtrA2/
Omi [84].
Recent studies show that the N-terminal mitochondrial localiza-
tion signal is necessary for some [68], but not all effects of PINK1 [71].
This suggests that PINK1 neuroprotection could involve cytosolic
targets even in models involving mitochondrially targeted injury. The
ability to form cytosolic complexes with parkin and DJ-1, with effects
on E3 ligase activity, has been recently reported [85]. On the other
hand, recombinant variants of PINK1 lacking the N-terminal domain
are still present in mitochondrial fractions due to binding interactions
with other proteins [86], so these studies do not negate the probability
of key mitochondrial targets for PINK1.
Similarly, PINK1 localization with respect to mitochondrial sub-
compartments is still unclear. While most studies indicate localization
predominantly near the innermitochondrial membrane [65,73,78,83],
PINK1 may also associate with outer membrane fractions to a lesser
extent [78]. Moreover, one study suggests that the kinase domain
faces outwards from the mitochondrion through an arrested import
mechanism [87]. Like other kinases [88], it is likely that PINK1 has
multiple functions in the cell involving dynamic trafﬁcking between
subcellular compartments and scaffold complexes, depending upon
post-translational modiﬁcations and proteolytic processing.
One of the challenges with studying PINK1 has been difﬁculty
detecting endogenous levels of the PINK1 protein. Thus, localization
and even degree of RNAi knockdown has often been estimated using
overexpressed tagged recombinant PINK1. As the degree of proteinoverexpression cannot be estimated without a reliable measure of
endogenous PINK1, it is possible that high levels of overexpression
saturate transport or processing mechanisms. Using an antibody
raised to the kinase domain, the major endogenous band detected in
SH-SY5Y cells is a processed form that lacks both the N- and C-
terminals, whereas recombinant C-terminal tagged PINK1 migrates as
a full-length species that nevertheless associates with mitochondrial
fractions [89]. While detection of tagged species can be markedly
enhanced by proteasome inhibition in agreement with other studies
[64], such treatments have little effect on endogenous bands.
Conversely, other studies have shown that processed PINK1 is not
limited to mitochondrial fractions, suggesting either efﬂux from
mitochondria [62] or other sites of proteolytic processing. Other
considerations include non-linearity of antibody responses, observa-
tions that one antibody may preferentially recognize one processed
form over another even if equivalent amounts are present, and effects
of as yet uncharacterized post-translational modiﬁcations on antibody
avidity. It is clear that muchwork remains to be done to illuminate the
distribution of PINK1 under different physiologic and injury states in
pertinent neuronal populations.
5. PINK1 loss-of-function has major effects on mitochondrial
morphology
Regardless of the major site(s) of PINK1 function, modulating
PINK1 expression shows major effects on mitochondrial morphology
in Drosophila (see below) and several mammalian studies (see
Table 1). Interestingly, silencing or knockout of PINK1 expression in
mice does not cause neuronal cell death [90,91], resulting instead in
decreased evoked striatal dopamine release [91] and reduced state 3
maximal respiration in the presence of ADP [92]. Cortical regions are
less susceptible to these changes, but these differences can be
overcome by H2O2 or heat shock, suggesting that the mice are well
compensated for the developmental absence of PINK1.
Drosophila studies show ﬂight muscle degeneration accompanied
by markedly swollen and enlarged mitochondria. Notably, PINK1 and
parkin ﬂies show similar phenotypes. While parkin overexpression
reverses effects of PINK1 loss-of-function on mitochondrial morphol-
ogy, the converse was not observed, suggesting that parkin functions
downstream of PINK1 [93–95]. The ability of parkin overexpression to
correct morphologic effects of PINK1 deﬁciency has also been
observed in mammalian cells [89,96]. Assuming that parkin over-
expressionmay act to directly reverse the deﬁcit left by reduced PINK1
function, the simplest model places parkin as a mediator of PINK1
mitoprotection (Fig. 2, top), although other potential mechanisms are
also compatible with the data (Fig. 2, bottom and legend).
Additional studies supporting a direct relationship between
PINK1 and parkin include observations that a parkin peptide can
be phosphorylated by ΔN-PINK1 in vitro [97] and demonstrating
physical interaction between overexpressed PINK1 and parkin in the
cytosol [85,98,99]. It remains to be discovered whether or not the
mitochondrial effects of altered PINK1 are modulated by parkin E3
ligase activity, nor is it known whether or not PINK1 kinase activity
is important for this interaction. With some exceptions (e.g. MAPKs),
activated kinases typically do not stably dock with their substrates,
but can form stable complexes with inhibitors, anchoring proteins
and scaffolds.
Both Drosophila and mammalian cell studies show ultrastructural
changes for PINK1 loss-of-function involving mitochondrial pallor
with decreased or disorganized cristae [89,100,101], which resemble
mitochondria in sporadic PD cybrid cell lines [102]. While some
proﬁles appear enlarged, it is unclear whether this reﬂects swelling or
fusion. The apparent size of ultrastructural proﬁles is inﬂuenced by the
angle between the plane of section and the longitudinal mitochondrial
axis, as well as by the degree of branching and tortuosity. In addition,
ﬂuorescence and molecular genetic data in Drosophila [100,101,103]
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Fig. 2. Hypothetical models for PINK1–Parkin interactions. Several effects of PINK1
deﬁciency can be complemented by overexpression of parkin in both mammalian and
invertebrate systems. 1) The simplest model places parkin as a downstreammediator of
a common PINK1–Parkin pathway that affects mitochondrial dynamics, although there
is disagreement in the literature over whether the ﬁssion–fusion balance is positively
(Drosophila) or negatively (mammalian cells, C. elegans) associated with PINK1 activity.
2) An alternative model is suggested by data showing opposite effects of PINK1 and
parkin activities on autophagy/mitophagy [89]. PINK1maintains healthymitochondrial
networks regulated by a steady state ﬁssion–fusion balance, and in the absence of
damage, there is no stimulus to induce autophagy. In PINK1 deﬁcient cells, ﬁssion and
autophagy are coordinately upregulated to isolate damaged and often swollen
segments of mitochondria, preventing propagation of calcium waves and release of
oxidants and other death mediators. Parkin overexpression augments selective
clearance of depolarized mitochondria [105]. Thus, PINK1 and parkin promote a similar
steady state phenotype of healthy mitochondrial networks by acting at different ends of
the process, with PINK1 maintaining mitochondrial health and parkin eliminating
damaged mitochondria. Experimentally increasing Drp1 indirectly protects against cell
injury by further enhancing the compensatory ﬁssion-autophagy process (rather than
by restoring a normal PINK1 function), while knockdown of Drp1 function and
increased Opa serve to exacerbate injury. These two models are not mutually exclusive,
and there is at least one other model inwhich both proteins may affect a similar process
through different mechanisms. For example, both parkin and PINK1 may function to
enhance mitochondrial biogenesis [49, 109], but parkin does not rescue the effects of
PINK1 deﬁciency in this context.
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opposite conclusions in the ﬁssion–fusion balance.
In PINK1 deﬁcient Drosophila, GFP-tagged mitochondria in long-
itudinal ﬂight muscle sections show a dishomogeneous distribution
with signiﬁcant clumping that is distinct from the clearly ﬁssioned
appearance elicited by knockdown of Marf (Mfn homolog) [103].
Surprisingly, immunostaining of GFP-tagged mitochondria in DA
neuron whole mount sections shows similar mitochondrial aggrega-
tion in both dPINK1 deﬁcient and dPINK1 overexpressing ﬂies [100].
However, the mechanisms may be different as analysis of cultured
Drosophila neurons, S2R cells and COS cells reveal that more PINK1
deﬁcient cells are scored as cells with elongated proﬁles compared
to dPINK1 overexpressing cells [100]. In Drosophila systems,
molecular manipulations to increase ﬁssion or decrease fusion pro-
tected against muscle degeneration, mitochondrial swelling and loss
of brain DA levels [100,101,103]. These include providing an extra
copy of Drp1 or decreasing levels or function of Opa1 or Mfn. On the
other hand, decreased Drp1 suppresses the effects of PINK1 over-
expression in the eye [101], and exacerbated injury in PINK1
deﬁcient ﬂies. Assuming that the effects of manipulating mitochon-
drial ﬁssion–fusion machinery directly reverses the effects of
insufﬁcient PINK1, these data suggest that the normal function of
PINK1 may be to promote ﬁssion [100,101]. Alternatively, data in
Drosophila muscle and testes suggest that the effects of PINK1 are
not mediated by a direct linear relationship with Drp1, as the
mitochondrial phenotypes are distinct and a modest deﬁcit in Drp1
causes lethality in PINK1 null ﬂies [103]. As discussed below, theeffects of Drp1 manipulation may also be compatible with modula-
tion of a compensatory mechanism that protects from the effects of
PINK1 deﬁciency.
In mammalian cells, three studies have shown the opposite
phenotype, namely that PINK1 deﬁcient cells exhibit fragmented
rather than fused mitochondria [34,89,96]. The changes observed in
stable deﬁcient states may be time dependent, as a transient siRNA
study showed no morphology changes at 12 d [49]. In mutant PINK1
patient ﬁbroblasts, human HeLa cells and human M17 neuronal cells,
signiﬁcantly increased percentages of PINK1 deﬁcient cells are scored
as showing fragmented rather than interconnected mitochondria
[34,96]. Using a different technique involving computerized analysis
of individual mitochondria within cells, average cellular indices of
mitochondrial interconnectivity and elongation are decreased with
PINK1 deﬁciency or Drp1 overexpression (as a positive control for
ﬁssion) and increased with either transient or stable overexpression
of wild type PINK1 and with a dominant negative Drp1 (as a positive
control for fusion) [89]. Ultrastructural analysis of several indepen-
dent PINK1 knockdown cell lines showed a mixture of small
fragmented proﬁles and large rounded, pale proﬁles, both with
diminished cristae density. The appearance of larger diameter proﬁles
has also been described in aging PINK1 KO mice [92] and in cells co-
expressing mutant α-synuclein and truncated PINK1 [78]. Confocal
microscopy with 3-D reconstruction shows that irregardless of
diameter, mitochondrial fragments are isolated from each other,
consistent with a ﬁssion-dependent process [89]. In contrast, over-
expression of PINK1 results in a more interconnected network. Finally,
live cell imaging was used to demonstrate that PINK1 deﬁcient cells
show reductions in the mobile fraction of mito-YFP, consistent with
reduced interconnectivity [34]. In light of recent reports of PINK1
associating with mitochondrial adapters for microtubule dependent
transport [86], this data could also be consistent with reduced overall
mitochondrial mobility. Irregardless, rates of mitochondrial fusion
were decreased in PINK1 deﬁcient cells when assayed using photo-
activated mito-GFP [34]. Taken together, these studies demonstrate a
shift in the ﬁssion–fusion balance to favor Drp1-dependent ﬁssion in
PINK1 deﬁcient cells.
In human neuronal cells, the mitochondrial fragmentation pheno-
type is suppressed by dominant negative Drp1 [89], Drp1 knockdown,
or Opa1/Mfn2 overexpression [34]. Overexpression of Drp1 promotes
further fragmentation. Furthermore, PINK1 knockdown cells exhibit
decreased phosphorylation of Drp1 at S637 through activation of
calcineurin phosphatase activity [34], while PINK1 overexpressing
cells exhibit Drp1 2D-gel mobility consistent with higher phosphor-
ylation states (SJ Cherra and CT Chu, unpublished data). Because Drp1
phosphorylation at S637 inhibits its ability to mediate ﬁssion [104],
these data are consistent with a role for PINK1 in suppressing ﬁssion.
Interestingly, suppressing Drp1 activity exacerbated cellular injury in
the setting of PINK1 deﬁciency [89], in agreement with Drosophila
studies, despite reversing the mitochondrial morphology changes.
Again, these data implicate ﬁssion as a response to injury elicited by
PINK1 deﬁciency.
6. Alternative models for PINK1–parkin interactions and
mitochondrial regulation
While direct studies of mitochondrial ﬁssion and fusion kinetics
may help resolve some issues, it is important to recognize that ﬁssion
and fusion are not the only modulators of the steady state appearance
of the mitochondrial network (Fig. 1). Selective clearance of smaller
somatic mitochondrial fragments through either axonal transport or
autophagic degradation, or alterations in delivery of newly synthe-
sized mitochondrial components, can each affect the distribution of
elongated or punctate mitochondria. A recent pair of studies that
together suggests an alternative model for PINK1–parkin interactions
(Fig. 2 bottom), may also partially resolve some of the controversies
25C.T. Chu / Biochimica et Biophysica Acta 1802 (2010) 20–28associated with the effects of Drp1 modulation between Drosophila
and human neuronal lines.
It has been elegantly demonstrated that parkin regulates not only
proteasomal degradation, but is recruited to chemically depolarized
mitochondriawhere it promotes their degradation through autophagy
[105]. While autophagy has been traditionally viewed as a nonselec-
tive bulk housekeeping process, recent work in injury and disease
models support the concept that selective mechanisms of targeted
degradation must also exist. For mitochondrial autophagy, eat-me
signals may include decreased membrane potential [41,105,106],
targets of mitogen activated protein kinase/extracellular signal
regulated protein kinase activity [18], or lipid oxidation [107].
Interestingly, given the E3 ligase function of parkin, certain forms of
ubiquitination may also be involved in autophagy regulation [108].
If parkin rescues from PINK1 deﬁciency by reconstituting a
downstream function of PINK1, it would be logical to surmise that
PINK1 may also function to promote clearance of damaged mitochon-
dria. Instead, we found the opposite: wild type PINK1 suppresses
injury-induced autophagy while PINK1 deﬁcient lines showed induc-
tion of autophagy and mitochondrial degradation [89]. Further
investigation revealed that parkin overexpression complements the
effects of PINK1 knockdown in human neuronal cells by further
enhancing autophagic clearance of mitochondria isolated by ﬁssion
[89]. Also, an intact autophagy machinery is essential for parkin-
mediated protection against cell death in PINK1 deﬁcient cells (RK
Dagda and CT Chu, unpublished data). These studies indicate that
PINK1 and parkin can promote a similar steady state phenotype of
healthy, elongated mitochondrial networks by acting at different ends
of the process, with PINK1 maintaining mitochondrial health and
parkin eliminating damaged mitochondria. Similarly, the ability of
ﬁssion mediators to rescue against injury in Drosophila PINK1
mutants, may relate to enhancing the isolation and clearance of
damaged mitochondria (Fig. 2, bottom). Undoubtedly both ﬁssion and
fusion are activated as an injury response (Fig.1), with the steady state
outcome on mitochondrial morphology dependent upon cell type-
and context-dependent differences in compensatory reserve and
susceptibility to injury.
A third model must also be considered, as it is possible that PINK1
and parkin regulate a common process or outcome through distinct
mechanisms. For example, PINK1 [49] and parkin [109] may be
implicated in mitochondrial biogenesis through different pathways.
Furthermore, although PINK1 does not rescue parkin null phenotypes
in Drosophila, parkin can still function upstream of PINK1 by
modulating its processing and subcellular distribution [63]. These
models are not mutually exclusive, and it is likely that multiple levels
of interaction exist depending upon the particular process regulated
by PINK1.
7. Towards a unifying model of PINK1 deﬁciency studies
If the primary role of PINK1 is to maintain healthy mitochondrial
networks, with perturbations in mitochondrial dynamics occurring
secondary to injury, what then contributes to mitochondrial or
cellular injury? The ﬁnal portion of this review will focus upon data
implicating 1) abnormal cristae structure and function, 2) calcium
dysregulation, and 3) oxidative stress, each of which may provide
signals to trigger mitochondrial remodeling and autophagy.
Abnormal cristae structure and membrane depolarization have been
consistently described in all mammalian culture studies of PINK1
deﬁciency (Table 1). Given that cristae are important for expanding
the surface area of the inner mitochondrial membrane available for
mitochondrial respiration, it is likely that these structural and
functional alterations are linked. PINK1 may play a primary role in
modulating the functional morphology of cristae, given its recently
reported associationwith mitoﬁlin [86]. These changes are unlikely to
occur purely as a nonselective consequence of PINK1 deﬁcient injury,as overexpression of PINK1 causes markedly increased cristae density
without eliciting an autophagic injury response [89]. The mechanisms
for abnormal electron transport chain function are still being
elucidated, and may include substrate limitation [110] or direct effects
on mitochondrial complex I function [111], although no consistent
change in expression of mitochondrial electron transport complex
components has been reported (Table 1). Given that changes in
mitochondrial membrane potential play important roles in regulating
axonal transport [112,113], mitophagy or apoptosis [114], additional
work on the role of PINK1 in modulating mitochondrial respiration
and membrane potential may yield new therapeutic directions.
Mitochondrial calcium dysregulation may play a key role in PINK1
deﬁcient cells [110] and in a combined mutant α-synuclein and
mutant PINK1model [78]. Under normal circumstances, mitochondria
play an important role in rapid buffering of cytosolic calcium, taking
up calcium into the matrix through a membrane potential-dependent
uniporter [115]. An unidentiﬁed sodium–calcium antiporter then
releases calcium back into the cell, preventing saturation of this
buffering system. In PINK1 deﬁcient human and mouse neurons,
defective antiporter function results in elevated basal mitochondrial
calcium levels and impaired buffering capacity [110]; inhibiting
calcium uptake into mitochondria protects against the effects of
overexpressed W437X PINK1 and A53T α-synuclein in rat neuro-
blastoma cells [78]. Among the effects of elevated cytosolic calcium
are activation of NADPH oxidase [110] and calcineurin, which
promotes ﬁssion in PINK1 knockdown cells [34]. Antioxidants reverse
glucose uptake deﬁcits and restore function of the electron transport
chain [34]. Interestingly, chronic lysosomal dysfunction results in
accumulation of mitochondria with calcium buffering deﬁcits and
enhanced sensitivity to calcium mobilizing injuries [116]. Likewise,
mitochondrial ﬁssion, which exacerbates cell death due to Drp1-
dependent recruitment of Bax, protects against injuries involving
propagating mitochondrial calcium waves [32]. Given that ﬁssion
plays a protective role in PINK1 deﬁcient cells [89,100,101,103], these
observations provide additional indirect support to the calcium
dysregulation model for PINK1 deﬁciency.
Oxidative stress has been implicated in eye degeneration caused
by dPINK1 inactivation in fruit ﬂies [117] and in several mammalian
neuronal systems [49,51,89]. While PINK1 has been implicated in a
FOXO3a-mediated ROS defense pathway [118], increased electron
leakage from dysfunctional respiration or calcium-mediated activa-
tion of NADPH oxidases could contribute to ROS generation in PINK1
deﬁcient cells. ROS-mediated damage to nearby respiratory compo-
nents and/or mtDNA could in turn set up a damaging positive
feedback loop to further amplify injury. Whether ROS is a primary
or secondary event, these species clearly contribute to injury.
Although there is little evidence of oxidative injury in PINK1
knockout mice other than aconitase inactivation [113], antioxidant
enzymes and pharmaceutical agents confer signiﬁcant protection
against several alterations observed in PINK1 deﬁcient Drosophila
[117] and human cells, including diminished membrane potential
[89,110].
It may be worth separating the potential signaling functions of
reactive oxygen species from pathologic levels of oxidative stress. For
instance, reversible redox inactivation of autophagy proteins that
remove LC3 from membranes may function as part of a physiologic
regulatory system that allows initiation of starvation-induced autop-
hagy [119]. Much higher levels of mitochondrial ROS, however, may
result in overactivation of autophagy through robust mitochondrial
ERK activation [15,18] or loss of physiologic feedback mechanisms
involving beclin 1 [120]. While autophagy is cytoprotective in the
context of PINK1 deﬁciency, beclin 1 independent autophagy
contributes to neurite retraction in the MPP+ and G2019S LRRK2
models [16,17]. As with ﬁssion/fusion and other potential therapeutic
targets, either insufﬁcient or excess stimulation of autophagy may
prove harmful unless properly balanced [39].
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Mitochondrial fragmentation, cristae loss and mitophagy have
been observed in human neurodegenerative diseases [121,122],
suggesting that perturbations in ﬁssion–fusion homeostasis and
autophagy could contribute to neuritic/synaptic dysfunction and
neurodegeneration in PD. Current data in models of autosomal
recessive PARK6 neurodegeneration suggest that aberrant cristae/
inner membrane function, calcium dysregulation and oxidative stress
trigger a series of pathogenic as well as compensatory pathways.
Coordinated activation of mitochondrial ﬁssion and autophagy
functions to isolate dysfunctional mitochondria [89], limiting cell
death, while fusion may also be activated to facilitate repair and
mtDNA stabilization [30].
Complementation of PINK1 deﬁcient states may be mediated by 1)
restoring pathways dependent upon PINK1 function, 2) reversing
pathologic pathways activated in its absence, or 3) facilitating success
of compensatory mechanisms. Given that stimulating ﬁssion or
autophagy can be beneﬁcial in some contexts and harmful in others,
additional studies arewarranted to distinguish cause from correlation,
and factors that determine success of a given compensatory or
protective response. Both direct and indirect effects of altered PINK1
kinase activity and/or localization could form valid targets for
therapeutic modulation. Understanding pathways of injury and
compensation is important therapeutically whether or not they
represent direct kinase substrates, as there are multiple mechanisms
to achieve a common phenotype of a healthy neuronal mitochondrial
network. Given the broad neuroprotective properties of PINK1 in both
toxic and genetic models of parkinsonian injury, elucidating the
normal function(s) of PINK1 offers exciting promise for therapies
effective in multiple forms of PD.
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